UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4300-4307

2008

Volltextzugriff (PDF)

Pharmacokinetic Assessment of Nevirapine and Metabolites in Human Immunodeficiency Virus Type 1-Infected Patients with Hepatic Fibrosis

Antimicrobial Agents and Chemotherapy, 2009-10, Vol.53 (10), p.4147-4152

2009

Volltextzugriff (PDF)

In vitro-in vivo correlation for nevirapine extended release tablets

Biopharmaceutics & drug disposition, 2009-12, Vol.30 (9), p.542-550

2009

Volltextzugriff (PDF)

Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography–tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007-09, Vol.856 (1), p.252-260

2007

Volltextzugriff (PDF)

Steady-State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir when Coadministered with Ritonavir

Antimicrobial Agents and Chemotherapy, 2007-07, Vol.51 (7), p.2436-2444

2007

Volltextzugriff (PDF)

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

Journal of clinical pharmacology, 2013-10, Vol.53 (10), p.1028-1038

2013

Volltextzugriff (PDF)

"Forgiving" a missed daily dose

AIDS research and human retroviruses, 2011-04, Vol.27 (4), p.345-346

Macgregor, Thomas R

2011

Volltextzugriff (PDF)

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

British journal of clinical pharmacology, 2014-12, Vol.78 (6), p.1407-1418

2014

Volltextzugriff (PDF)

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine

Pharmacogenetics and genomics, 2011-11, Vol.21 (11), p.721-730

2011

Volltextzugriff (PDF)

Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study

The Pediatric infectious disease journal, 2014-07, Vol.33 (7), p.e173-e179

2014

Volltextzugriff (PDF)

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

Antiviral therapy, 2005-01, Vol.10 (4), p.489-498

2005

Volltextzugriff (PDF)

Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

Journal of clinical pharmacology, 2011-07, Vol.51 (7), p.1061-1070

2011

Volltextzugriff (PDF)

Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51)

Journal of acquired immune deficiency syndromes (1999), 2008-04, Vol.47 (4), p.429-440

2008

Volltextzugriff (PDF)

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study

Antiviral therapy, 2005, Vol.10 (1), p.145-155

2005

Volltextzugriff (PDF)

Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers

European journal of clinical pharmacology, 2011-03, Vol.67 (3), p.277-281

2011

Volltextzugriff (PDF)

Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil Fumarate Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open‐Label, Prospective Study

Basic & clinical pharmacology & toxicology, 2011-03, Vol.108 (3), p.163-170

2011

Volltextzugriff (PDF)

Case-Control Exploration of Relationships Between Early Rash or Liver Toxicity and Plasma Concentrations of Nevirapine and Primary Metabolites

HIV clinical trials, 2007-11, Vol.8 (6), p.391-399

2007

Volltextzugriff (PDF)

Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers

HIV clinical trials, 2004-11, Vol.5 (6), p.371-382

2004

Volltextzugriff (PDF)

Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil Fumarate Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open-Label, Prospective Study: PHARMACOKINETIC INTERACTION BETWEEN BILR 355 AND EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE

Basic & clinical pharmacology & toxicology, 2011-03, Vol.108 (3), p.163-170

2011

Volltextzugriff (PDF)

Pharmacokinetic Characterization of Three Doses of Tipranavir Boosted with Ritonavir on Highly Active Antiretroviral Therapy in Treatment-Experienced HIV-1 Patients

HIV clinical trials, 2010-01, Vol.11 (1), p.28-38

2010

Volltextzugriff (PDF)

Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study

HIV clinical trials, 2005-09, Vol.6 (5), p.254-261

2005

Volltextzugriff (PDF)

Pharmacokinetics of transdermally delivered clonidine

Clinical pharmacology and therapeutics, 1985-09, Vol.38 (3), p.278-284

1985

Volltextzugriff (PDF)

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

Biopharmaceutics & drug disposition, 1999-09, Vol.20 (6), p.285-291

1999

Volltextzugriff (PDF)

Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea-pigs

Journal of pharmacy and pharmacology, 1983-01, Vol.35 (1), p.38-42

1983

Volltextzugriff (PDF)

In Vitro Protein Binding Behavior of Dipyridamole

Journal of pharmaceutical sciences, 1991-02, Vol.80 (2), p.119-120

1991

Volltextzugriff (PDF)

1 – 25 von 342

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(307)
Mit Volltextzugriff
(300)

Publikationsform

Sprache

Englisch
(340)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(193)
Life Sciences & Biomedicine
(103)
Physics
(90)
Humans
(89)
Physical Sciences
(79)
Female
(64)
Male
(64)
Nuclear Physics And Radiation Physics
(48)
Physics Of Elementary Particles And Fields
(46)
Adult
(39)
Biological And Medical Sciences
(39)
Physics, Nuclear
(39)
Middle Aged
(38)
Medical Sciences
(35)
Physics, Particles & Fields
(31)
Nuclear Experiment
(30)
Pharmacology & Pharmacy
(29)
Polymorphism, Single Nucleotide
(24)
Animals
(22)
Nuclear Physics
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

Pharmacokinetic Assessment of Nevirapine and Metabolites in Human Immunodeficiency Virus Type 1-Infected Patients with Hepatic Fibrosis

In vitro-in vivo correlation for nevirapine extended release tablets

Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography–tandem mass spectrometry

Steady-State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir when Coadministered with Ritonavir

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

"Forgiving" a missed daily dose

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine

Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51)

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study

Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers

Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil Fumarate Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open‐Label, Prospective Study

Case-Control Exploration of Relationships Between Early Rash or Liver Toxicity and Plasma Concentrations of Nevirapine and Primary Metabolites

Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers

Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil Fumarate Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open-Label, Prospective Study: PHARMACOKINETIC INTERACTION BETWEEN BILR 355 AND EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE

Pharmacokinetic Characterization of Three Doses of Tipranavir Boosted with Ritonavir on Highly Active Antiretroviral Therapy in Treatment-Experienced HIV-1 Patients

Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study

Pharmacokinetics of transdermally delivered clonidine

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea-pigs

In Vitro Protein Binding Behavior of Dipyridamole

Suchergebnisse filtern